PegBio Co., Ltd.
派格生物医药(杭州)股份有限公司
02565.HK
Develops peptide and small molecule drugs for chronic and metabolic diseases, including type 2 diabetes, obesity, NASH and OIC, with a lead near-commercialized GLP-1 receptor agonist (PB-119). Operates in China.
Biotech & PharmaChapter 18ASponsorCICCCounselDavis Polk & Wardwell
Filings
The documents are on HKEXnews; we link to the originals.
| 2025-05-19 | Prospectus | HKEXnews |
Matters the filing discloses
From the company’s latest filing; open a kind of matter to see how other companies disclosed it.